PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Abbott Laboratories”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 37 records · Page 2Linked to original sources
PubMed2001

Rapid Access to Complex Molecular Architectures via o-Azaquinones We thank Dr. D. H. Huang, G. Siuzdak, and Dr. R. Chadha for NMR spectroscopic, mass spectrometric, and X-ray crystallographic assistance, respectively. This work was supported financially by The Skaggs Institute for Chemical Biology, the National Institutes of Health (USA), a predoctoral fellowship from the National Science Foundation (P.S.B), and grants from ArrayBiopharma, Pfizer, Glaxo, Merck, Schering Plough, Hoffmann-La Roche, Boehringer Ingelheim, DuPont, and Abbott Laboratories.

Explore the source record for details and available documents.

Journal Article↗
PubMed2001

Total Synthesis of Apoptolidin: Part 1. Retrosynthetic Analysis and Construction of Building Blocks We thank Dr. D. H. Huang and Dr. G. Siuzdak for NMR spectroscopic and mass spectrometric assistance, respectively. This work was financially supported by the National Institutes of Health (USA), the Skaggs Institute for Chemical Biology, American Biosciences, a pre-doctoral fellowship from Boehringer Ingelheim (Y.L.), a postdoctoral fellowship the George Hewitt Foundation (K.C.F.), and grants from Abbott Laboratories, ArrayBiopharma, Bayer, Boehringer Ingelheim, DuPont, Glaxo, Hoffmann-LaRoche, Merck, Novartis, Pfizer, and Schering Plough.

Explore the source record for details and available documents.

Journal Article↗
PubMed2001

Total Synthesis of Apoptolidin: Part 2. Coupling of Key Building Blocks and Completion of the Synthesis We thank Dr. C. Khosla and Dr. Y. Hayakawa for generous gifts of apoptolidin, and Dr. D. H. Huang and Dr. G. Siuzdak for NMR spectroscopic and mass spectrometric assistance, respectively. This work was financially supported by the National Institutes of Health (USA), the Skaggs Institute for Chemical Biology, American Biosciences, a predoctoral fellowship from Boehringer Ingelheim (to Y.L.), a postdoctoral fellowship the George Hewitt Foundation (to K.C.F.), and grants from Abbott Laboratories, ArrayBiopharma, Bayer, Boehringer Ingelheim, DuPont, Glaxo, Hoffmann-LaRoche, Merck, Novartis, Pfizer, and Schering Plough.

Explore the source record for details and available documents.

Journal Article↗
PubMed2005

Costs and outcomes of extended-release vs. immediate-release clarithromycin for lower respiratory tract infections.

We used decision-analysis modeling to compare costs and outcomes of clarithromycin extended-release (Biaxin XL, Abbott Laboratories, Abbott Park, Illinois, USA) and clarithromycin immediate-release (Biaxin, Abbott Laboratories, Abbott Park, Illinois, USA) for outpatients with lower respiratory tract infections (LRTI). More patients achieved clinical cure with extended-release (83.9%) versus immediate-release (72.8%); fewer discontinued due to adverse events. Total costs with extended-release were $32 (16%) less; incorporating greater adherence for extended-release (once-daily) therapy resulted in greater savings. Results indicate that clarithromycin extended-release is cost-saving compared with immediate-release for LRTI.

Anti-Bacterial Agents↗